A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors

Brief description of study

The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab (a PD-L1 inhibitor) or tremelimumab (a CTLA-r inhibitor) in participants with advanced solid tumors.


Clinical Study Identifier: s16-00039
ClinicalTrials.gov Identifier: NCT02718911
Principal Investigator: Leena Gandhi
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.